Actinium Pharmaceuticals Inc. (NYSEAMERICAN:ATNM) and Seres Therapeutics Inc. (NASDAQ:MCRB) compete against each other in the Biotechnology sector. We will contrast them and contrast their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals Inc.	N/A	0.00	23.65M	-0.22	0.00
Seres Therapeutics Inc.	28.27M	9.58	98.94M	-2.62	0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 has Actinium Pharmaceuticals Inc. and Seres Therapeutics Inc.’s return on equity, net margins and return on assets.

	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals Inc.	0.00%	-139.9%	-106.2%
Seres Therapeutics Inc.	-349.98%	0%	-72.2%

Risk and Volatility

A beta of 2.59 shows that Actinium Pharmaceuticals Inc. is 159.00% more volatile than S&P 500. Seres Therapeutics Inc.’s 79.00% more volatile than S&P 500 volatility due to the stock’s 1.79 beta.

Liquidity

Actinium Pharmaceuticals Inc. has a Current Ratio of 3.7 and a Quick Ratio of 3.7. Competitively, Seres Therapeutics Inc.’s Current Ratio is 2 and has 2 Quick Ratio. Actinium Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Seres Therapeutics Inc.

Analyst Recommendations

The Ratings and Recommendations for Actinium Pharmaceuticals Inc. and Seres Therapeutics Inc. are featured in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Actinium Pharmaceuticals Inc.	0	0	0	0.00
Seres Therapeutics Inc.	0	0	4	3.00

On the other hand, Seres Therapeutics Inc.’s potential upside is 112.12% and its consensus target price is $14.

Insider & Institutional Ownership

Actinium Pharmaceuticals Inc. and Seres Therapeutics Inc. has shares owned by institutional investors as follows: 12.8% and 78%. Insiders owned 0.2% of Actinium Pharmaceuticals Inc. shares. On the other hand, insiders owned about 1.2% of Seres Therapeutics Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Actinium Pharmaceuticals Inc.	-0.02%	11.69%	26.51%	-3.89%	44.16%	60.18%
Seres Therapeutics Inc.	5.72%	1.95%	-25.06%	-27.06%	-34.17%	38.94%

For the past year Actinium Pharmaceuticals Inc.’s stock price has bigger growth than Seres Therapeutics Inc.

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The companyÂ’s proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its lead product candidate is Iomab-B that is in Phase III clinical studies in refractory or relapsed acute myeloid leukemia (AML) patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60; and Actimab-M that is in Phase I clinical trials for patients with relapsed or refractory multiple myeloma. In addition, it utilizes its alpha-particle immunotherapy technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. Its product candidates in pre-clinical development comprise SER-301, a synthetic Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-155, an Ecobiotic microbiome therapeutic for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.